Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

BACKGROUND: Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mG...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansoor, Wasat, Arkenau, Hendrik-Tobias, Alsina, Maria, Shitara, Kohei, Thuss-Patience, Peter, Cuffe, Sinead, Dvorkin, Mikhail, Park, David, Ando, Takayuki, Van Den Eynde, Marc, Beretta, Giordano D., Zaniboni, Alberto, Doi, Toshihiko, Tabernero, Josep, Ilson, David H., Makris, Lukas, Benhadji, Karim A., Van Cutsem, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205879/
https://www.ncbi.nlm.nih.gov/pubmed/33713215
http://dx.doi.org/10.1007/s10120-021-01156-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205879/
https://www.ncbi.nlm.nih.gov/pubmed/33713215
http://dx.doi.org/10.1007/s10120-021-01156-x

Ejemplares similares